NEW YORK, April 10, 2017 /PRNewswire/ --
On Friday, April 07, 2017, US markets saw
San Jose, California headquartered Align Technology Inc.'s stock edged 0.39% lower, to close the day at $114.74. The stock recorded a trading volume of 511,730 shares. Align Technology's shares have gained 8.90% in the last one month, 21.96% in the previous three months, and 57.05% in the past one year. The Company's shares are trading 10.04% and 21.29% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing digital services, are trading at a PE ratio of 49.22. Additionally, the stock has a Relative Strength Index (RSI) of 70.70. Visit us today and download your complete report on ALGN for free at:
On Friday, shares in San Diego, California headquartered ResMed Inc. ended the session 0.03% lower at $69.03, with a total volume of 604,072 shares traded. ResMed's shares have gained 11.62% in the last three months and 20.27% in the previous one year. Shares of the Company, which designs, develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, are trading at a PE ratio of 29.27. The stock is trading 6.04% above its 200-day moving average. Moreover, the Company's shares have an RSI of 35.48. The complimentary research report on RMD can be accessed at:
On Friday, shares in Waltham, Massachusetts headquartered Corindus Vascular Robotics Inc. recorded a trading volume of 457,143 shares. The stock ended the day 4.88% lower at $1.17. Corindus Vascular Robotics' stock has surged 11.43% in the last one month and 67.02% in the previous three months. Furthermore, the stock has gained 15.84% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 27.10% and 14.67%, respectively. In addition, shares of Corindus Vascular Robotics, which designs, manufactures, and sells precision vascular robotic-assisted systems for use in interventional vascular procedures, have an RSI of 51.46. Register for free on Stock-Callers.com and download the PDF research report on CVRS at:
Sylmar, California headquartered Second Sight Medical Products Inc.'s stock finished Friday's session 1.69% higher at $1.20, with a total volume of 214,453 shares traded. The Company's shares are trading below its 50-day and 200-day moving averages by 20.54% and 53.32%, respectively. Shares of Second Sight Medical Products, which develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the US, Italy, Germany, France, and Canada, have an RSI of 37.36. Get free access to your research report on EYES at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All